Kraig Biocraft Laboratories Successfully Completes Cocooning in First Commercial Production Run of BAM-1 Spider Silk Hybrids
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced the successful completion of cocoon production for its first commercial run of BAM-1 spider silk hybrids. The production, launched 30 days ahead of schedule, achieved a 10x increase in volume compared to spring trials, generating over 325 pounds of cocoons. This marks the largest batch of recombinant spider silk ever produced. Kraig Labs aims to scale up production further to meet its metric-ton-level goal, leveraging the robustness of BAM-1 hybrids for large-scale manufacturing. CEO Kim Thompson emphasized the success and potential for rapid scale-up in 2024.
- Successfully completed cocoon production for the first commercial run of BAM-1 hybrids.
- Production launched 30 days ahead of schedule.
- Achieved a 10x increase in production volume compared to spring trials.
- Generated over 325 pounds of recombinant spider silk cocoons.
- Largest batch of recombinant spider silk ever produced.
- BAM-1 hybrids designed for improved robustness for large-scale manufacturing.
- Strong confidence in achieving metric-ton-level production goals.
- Potential for rapid scale-up in 2024.
- No financial data provided to indicate revenue or profit impact.
- Potential challenges in scaling up production to metric-ton levels.
- No concrete timelines for further commercial expansion.
ANN ARBOR, Mich., June 17, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has successfully completed cocoon production for the first commercial production run of its BAM-1 hybrids. The Company launched the BAM-1 hybrids 30 days ahead of schedule based on the overwhelming success of its spring production trials.
During the spring trials, Kraig labs raised the two separate BAM-1 parental lines with overwhelming success. At the end of those trials, the BAM-1 parent lines were cross-mated to create this first batch of commercial production BAM-1 hybrids.
This rearing of the BAM-1 hybrids represents a 10X increase in production volume when compared to the spring trials. This cycle has generated more than 325 pounds of recombinant spider silk cocoons that will be processed into finished recombinant spider silk. This is the largest batch of recombinant spider silk cocoons ever produced.
The BAM-1 hybrids are the latest development in the Company's commercialization of recombinant spider silk. They were specifically designed to address the identified need for improved robustness to meet large-scale spider silk manufacturing needs.
Having proven its production efficiency, the Company is now preparing for further commercial expansion of the BAM-1 parental lines and significant scale-up in BAM-1 hybrids. Based on the results of production operations, the Company remains confident that it will achieve its metric-ton-level spider silk production goal.
"This first commercial production rearing of BAM-1 hybrids was a great success, representing the largest single batch we have ever produced to date. This production batch is just the beginning of what we believe will be a very exciting and rapid scale-up of spider silk production in 2024," said Company Founder and CEO, Kim Thompson. "We will continue to move forward, taking smart risks, as we lead the commercialization of cost-effective and eco-responsible spider silk."
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the significance of Kraig Biocraft Laboratories' BAM-1 hybrid production?
How much recombinant spider silk cocoons did Kraig Biocraft Laboratories produce in its first commercial run?
What are the future goals for Kraig Biocraft Laboratories?
When did Kraig Biocraft Laboratories complete the cocooning for BAM-1 hybrids?
What is the stock symbol for Kraig Biocraft Laboratories?
